Peptides and related compounds having thrombopoietic activity

• US 7,332,474 B2
• Filed: 10/10/2002
• Issued: 02/19/2008
• Est. Priority Date: 10/11/2001
• Status: Expired due to Fees

• Current Assignee: Amgen Inc.
• Original Assignee: Amgen Inc.
• Inventors: Min, Hosung, Hartley, Cynthia, Sitney, Karen C.
• Primary Examiner(s): Gupta; Anish
• Assistant Examiner(s): GUDIBANDE, SATYANARAYAN R
• Application Number:
  US10/269,806
• Publication Number:
  US 20030176352A1
• Time in Patent Office: 1,958 Days
• Field of Search: None
• US Class Current: 530/317
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/04 Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: C07K 14/524 Thrombopoietin, i.e. C-MPL ligand

Abstract

The present invention relates generally to novel peptides and related compounds that have thrombopoietic activity. The compounds of the invention may be used to increase production of platelets or platelet precursors (e.g. megakaryocytes) in a mammal.

Claims

1. A compound that binds to an mpl receptor comprising a sequence which is selected from the group consisting of SEQ ID NO 2 to SEQ ID NO 30, inclusive

2. The compound according to claim 1 which is cyclic.

3. The compound according to claim 1 wherein at least one of the amino acid residues has a D configuration.

4. The compound according to claim 1 wherein all of the amino acid residues have a D configuration.

5. A dimer or multimer of the compounds according to claim 1.